News Quantified

RVMD – revolution medicines, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy

FDA Breakthrough Status For Daraxonrasib Might Change The Case For Investing In Revolution Medicines (RVMD) [Yahoo! Finance]

Revolution Medicines (NASDAQ:RVMD) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.

Healthcare stocks are red-hot. Here are 3 picks from a fund manager up 41% this year. [Business Insider]

Revolution Medicines (NASDAQ:RVMD) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.

3.4%

MISS

-4.7%

MISS

11.3%

MISS

-3.5%

MISS

Form 4 Revolution Medicines, For: Dec 16 Filed by: Cislini Jeff

Form 4 Revolution Medicines, For: Dec 16 Filed by: GOLDSMITH MARK A

Form 4 Revolution Medicines, For: Dec 16 Filed by: Horn Margaret A

Form 4 Revolution Medicines, For: Dec 16 Filed by: Kelsey Stephen Michael

Form 4 Revolution Medicines, For: Dec 16 Filed by: Anders Jack

Top News Gainers

4/29 Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models 8.7%

3/18 Form SEC STAFF LETTER Revolution Medicines, 7.6%

4/16 Bill.com Holdings (NASDAQ: RVMD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $27.00 price target on the stock. 6.6%

2/24 Form SC 13G Revolution Medicines, Filed by: Cormorant Asset Management, LP 4.5%

2/14 Form 4 Revolution Medicines, For: Feb 12 Filed by: Kelsey Stephen Michael 3.8%

2/18 Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares 3.3%

3/20 Form 8-K Revolution Medicines, For: Mar 18 3.1%

4/21 Form 8-K Revolution Medicines, For: Apr 17 2.6%

2/12 Form 3 Revolution Medicines, For: Feb 12 Filed by: GOEDDEL DAVID V 2.4%

4/17 Bill.com Holdings (NASDAQ: RVMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 1.7%

Top News Decliners

3/12 Form SEC STAFF LETTER Revolution Medicines, -17.9%

5/1 Bill.com Holdings (NASDAQ: RVMD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $38.00 price target on the stock. -5.7%

2/20 Form 4 Revolution Medicines, For: Feb 18 Filed by: Exter Neil -3.9%

2/14 Form SC 13G/A Revolution Medicines, Filed by: Boxer Capital, LLC -2.3%

3/30 Form 10-K Revolution Medicines, For: Dec 31 -1.9%

3/18 Revolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor Program -1.6%

2/19 Revolution Medicines Joins Amgen and Mirati in Quest for New Type of Cancer Drugs [Yahoo! Finance News] -0.9%

3/9 New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute -0.4%

2/13 Form SC 13G Revolution Medicines, Filed by: Boxer Capital, LLC -0.3%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day